123 related articles for article (PubMed ID: 3127851)
21. Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients.
Midha KK; Hawes EM; Hubbard JW; Korchinski ED; McKay G
Psychopharmacology (Berl); 1988; 96(2):206-11. PubMed ID: 3148147
[TBL] [Abstract][Full Text] [Related]
22. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
23. Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
Norman TR; Marriott PF; Kimber NM; Burrows GD
Int Clin Psychopharmacol; 1987 Oct; 2(4):299-305. PubMed ID: 3693869
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
25. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
[TBL] [Abstract][Full Text] [Related]
26. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
[No Abstract] [Full Text] [Related]
27. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
28. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
[TBL] [Abstract][Full Text] [Related]
30. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
McCreadie R; Mackie M; Morrison D; Kidd J
Br J Psychiatry; 1982 Mar; 140():280-6. PubMed ID: 7093596
[TBL] [Abstract][Full Text] [Related]
31. Fluphenazine pharmacokinetics and therapeutic response.
Dysken MW; Javaid JI; Chang SS; Schaffer C; Shahid A; Davis JM
Psychopharmacology (Berl); 1981; 73(3):205-10. PubMed ID: 6787637
[TBL] [Abstract][Full Text] [Related]
32. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
33. The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics.
Rifkin A; Quitkin F; Kane J; Klein DF; Ross D
Biol Psychiatry; 1979 Jun; 14(3):499-508. PubMed ID: 224958
[TBL] [Abstract][Full Text] [Related]
34. Persistence of fluphenazine in plasma after decanoate withdrawal.
Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
[TBL] [Abstract][Full Text] [Related]
35. Fluphenazine plasma levels and clinical response.
Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
[TBL] [Abstract][Full Text] [Related]
36. The prolactin response in patients receiving neuroleptic therapy. The effect of fluphenazine decanoate.
Dotti A; Lostia O; Rubino IA; Bersant G; Carilli L; Zorreta D
Prog Neuropsychopharmacol; 1981; 5(1):69-77. PubMed ID: 7280130
[No Abstract] [Full Text] [Related]
37. Late (4-8 years) outcome of treatment with megadoses of fluphenazine enanthate in drug-refractory schizophrenics.
Dencker SJ; Enoksson P; Johansson R; Lundin L; Malm U
Acta Psychiatr Scand; 1981 Jan; 63(1):1-12. PubMed ID: 7234461
[TBL] [Abstract][Full Text] [Related]
38. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
Turbott J; Villiger J; Hunter L
Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
[TBL] [Abstract][Full Text] [Related]
39. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
[TBL] [Abstract][Full Text] [Related]
40. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.
Wistedt B; Jørgensen A; Wiles D
Psychopharmacology (Berl); 1982; 78(4):301-4. PubMed ID: 6818587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
